Introduction contemporary incidence, management, and outcomes of perioperative VTE after major noncardiac surgery remain limited. [3] [4] [5] [6] [7] We evaluated national trends in perioperative VTE incidence and outcomes associated with noncardiac surgery in a large administrative database of hospital admissions from the United States.
Methods

Study Population
The Healthcare Cost and Utilization Project's (HCUP) National Inpatient Sample (NIS) was used to identify patients undergoing major noncardiac surgery during the years 2005 to 2013. The HCUP NIS is a national administrative database of all discharge-level data collected from a 20% stratified sample of U.S. hospitals until 2012 and a 20% stratified sample of discharges among all U.S. hospitals thereafter.
Given the low prevalence of VTE in younger cohorts, patients 45 years or older with a principal International Classification of Diseases, Ninth Revision (ICD-9) procedure code for a major therapeutic operating room procedure (HCUP Procedure Class 4) were included in the analysis. Principal Clinical Classifications Software (CCS) procedure codes, aggregates of related primary ICD9 procedure codes by surgical subtype, were used to exclude patients who underwent cardiac procedures (n ¼ 1,465,792), cardiac surgery and cardiac transplantation (n ¼ 522,635), bone marrow transplantation (n ¼ 16,934), ophthalmologic surgery (n ¼ 11,458), radiation therapy (n ¼ 8,216), dental surgery (n ¼ 1,570), and nonoperating room procedures (n ¼ 311). 8 Patients with ICD-9 procedure codes for venous thrombectomy or embolectomy (n ¼ 1,389) and inferior vena cava (IVC) filter placement in the primary position were also excluded (n ¼ 133,446). Major noncardiac surgery CCS procedure codes were clustered into 12 major surgical subtypes for analysis: endocrine, general, genitourinary, gynecologic, neurosurgery, obstetrics, orthopaedic, otolaryngology, skin and breast, thoracic, noncardiac solid-organ transplant, and vascular surgery. Perioperative VTE diagnoses during the index surgical hospitalization were identified using ICD-9 diagnosis codes for acute PE (415.1Â) and lower extremity DVT (451.1Â, 451.81, 453.2, 453.4Â). 
In-Hospital Management and Outcomes
Infusion of thrombolytic agent (99.10) or pulmonary angiography and catheter-based thrombolysis (procedure codes 99.10 and 88.43) were defined based on ICD-9 procedure codes during inpatient hospitalization. 9 IVC filter placement (38.7) was defined by an ICD-9 procedure code in a nonprimary position. The primary study outcome was in-hospital allcause mortality.
Statistical Analysis
Continuous variables were reported as mean AE standard deviation (SD) and compared using the Student's t-test. 
Sensitivity Analyses
Several sensitivity analyses were performed to validate the study findings. To exclude cases in which VTE may have preceded the primary noncardiac surgery, a sensitivity analysis was performed in the cohort of patients undergoing surgery within the first 48 hours of hospital admission. To account for declines in overall length of stay over time among patients hospitalized for surgery, rates of VTE per 100 inpatient hospital days were also determined.
Results
A total of 9,431,442 hospitalizations for major noncardiac surgery met the inclusion criteria (►supplementary Fig. S1 
Surgery-Specific Risks
In unadjusted analyses, patients undergoing thoracic surgery (2.0%) and vascular surgery (1.8%) had the highest absolute risks of perioperative VTE (►Fig. In-hospital placement of an IVC filter was performed in 24,014 (24.1%) patients with perioperative VTE. IVC filters were placed in 41.0% of patients with DVT and PE, 24.7% of patients with DVT alone, and 18.1% of patients with PE alone. Among patients with perioperative PE, systemic thrombolytic therapy was administered in 3.3% of cases and catheterdirected thrombolysis was performed in 0.3% of cases.
Outcomes of Perioperative VTE
In-hospital mortality was higher in patients with perioperative VTE versus those without VTE in unadjusted analyses (8.2 vs. 1.5%, p < 0.001) and after adjustment for clinical covariates (aOR: 3.12, 95% CI: 3.05-3.20). Increased odds of mortality after multivariable adjustment were observed for patients with perioperative PE versus those without PE (aOR: 4.96, 95% CI: 4.80-5.13 for PE) and perioperative DVT versus those without DVT (aOR: 2.10, 95% CI: 2.03-2.18). Among patients with perioperative VTE, mortality was significantly higher for patients with PE than patients with DVT (11.2 vs. 6.4%, p < 0.001).
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included advancing age, male sex, obesity, heart failure, malignancy, anemia, and a history of prior VTE. In adjusted analyses, patients undergoing thoracic and noncardiac vascular surgery had the highest risks of perioperative VTE. The observed increase in the incidence of perioperative VTE occurred over time despite a renewed focus on the importance of perioperative VTE prophylaxis as an unmet need and public health crisis.
11 Risk assessment models to predict VTE risk have been developed and validated in multiple surgical subspecialties, 12-16 thereby enabling providers to identify patients who might derive the greatest benefit from appropriate VTE thromboprophylaxis. There is evidence that providers have increased adherence to perioperative VTE prophylaxis over time. Among patients undergoing colorectal surgery, for example, the rate of perioperative pharmacological thromboprophylaxis increased substantially from 31.6% in 2006 to 86.4% in 2011. However, there is conflicting evidence regarding associations between increased rates of pharmacological thromboprophylaxis and declines in perioperative VTE. 14,17,18 Data on in-hospital pharmacological thromboprophylaxis were not available from the NIS dataset; so, its impact on VTE incidence cannot be assessed in the present study. However, based on the trends reported from individual surgical subspecialties, it is possible that rates of perioperative pharmacological thromboprophylaxis increased nationally during the analysis period.
17
The etiology of increasing rates of VTE may also be linked to changes in approaches to clinical diagnosis. With increasing awareness of perioperative VTE risk, novel risk scores and prediction rules, and high-resolution multidetector CT angiography for PE, increased diagnostic sensitivity may be at least partially responsible for the increased incidence of perioperative VTE over time. In fact, a rising incidence of VTE has also been reported among nonsurgical hospitalized patients.
19
Finally, the observed increases in VTE incidence may be related to changes in burden of risk factors for venous thromboembolic disease, or increasing surgical case complexity over time.
In this analysis, mortality associated with perioperative VTE declined over time. This finding is consistent with trends described in nonsurgical and surgical subspecialty populations with acute VTE. 4, [20] [21] [22] [23] In a recent report from the Computerized Registry of Patients with Venous Thromboembolism (RIETE), a multinational, observational cohort study of patients with any diagnosis of VTE, risk-adjusted all-cause mortality rates associated with acute PE declined substantially between 2001 and 2013. 21 There was an increased use of low-molecular-weight heparins, thrombolytic therapy, and surgical embolectomy over time. It is conceivable that similar trends occurred in the perioperative population, and that these changes in clinical management may have contributed to improved outcomes. Alternatively, improved VTE case fatality may be related to enhanced diagnostic sensitivity for VTE and identification of lower risk patients, thereby leading to a selection bias in case fatality over time. 23 Changes in the diagnostic sensitivity of thoracic imaging may be related to the observed declines in mortality among patients with perioperative PE, but not perioperative DVT. Changing patient's risk profiles over time might also contribute to the observed declines in perioperative VTE mortality, but these trends persisted even after adjustment for baseline demographics and relevant comorbidities. Vena cava filter placement was performed in 24.1% of patients with VTE undergoing noncardiac surgery, despite little data to support the efficacy of filter placement for VTE and significant inter-hospital variation reported in practice. [24] [25] [26] In the present analysis, catheter-directed and systemic thrombolytic therapies were infrequently used in the setting of noncardiac surgery. This is likely related to the anticipated risks of Venous Thromboembolism with Noncardiac Surgery Smilowitz et al. e87
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surgical site bleeding associated with thrombolytic therapies in this context. There are several limitations of this analysis. First, the data are derived from diagnosis and procedure codes recorded in a large nationwide administrative database of inpatient hospitalizations. As a consequence, data may be subject to bias, errors in reporting and coding, and the diagnosis of VTE may be underreported. As the NIS captures only in-hospital administrative data, it may underestimate the true incidence of perioperative VTE, since more than one-third of postoperative VTEs occur postdischarge.
7,27-30 A particularly vulnerable period is the first month after hospital discharge, when pharmacological thromboprophylaxis is often not utilized. Similarly, deaths that occurred after hospital discharge were not recorded. Furthermore, the NIS database does not include patients undergoing ambulatory or same-day surgery, and risks of VTE in this setting could not be determined. Second, the present analysis was limited to adults aged !45, a population enriched for cardiovascular events and at the greatest risk for VTE. 31 Trends in perioperative VTE were not determined for younger, low-risk patient groups. Third, data on in-hospital and discharge medical management were not available from the NIS database, and use of antiplatelet agents, unfractionated and low-molecularweight heparins, vitamin K antagonists, and direct oral anticoagulants for VTE prophylaxis and treatment could not be determined. The absence of data on rates of VTE prophylaxis during the study period limits the interpretation of VTE trends. Similarly, bleeding complications associated with VTE Venous Thromboembolism with Noncardiac Surgery Smilowitz et al. e88
prophylaxis and treatment could not be determined. Fourth, the sequence of surgery preceding VTE cannot be definitively established in this administrative database. However, patients with primary procedure codes for surgeries intended to treat VTE, such as venous thrombectomy and embolectomy, were excluded from the analysis. Furthermore, patients would be unlikely to undergo major nonvascular, noncardiac surgery in the setting of a known acute DVT or PE in most cases.
In conclusion, this is the largest analysis of in-hospital perioperative VTE in patients undergoing major noncardiac surgery in the United States. Perioperative VTE occurred in approximately 1% of patients undergoing major noncardiac surgery, with an increasing incidence over time. In-hospital mortality was significantly higher among patients with perioperative VTE in comparison to those without VTE. Overall perioperative VTE case fatality rates declined between 2005 and 2013, with significant decreases observed among patients with perioperative PE, but not DVT. Additional measures to prevent and improve management of perioperative VTE are warranted. Venous Thromboembolism with Noncardiac Surgery Smilowitz et al. e89
